

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 24, 2025

Mouse Anti-Human AFP (C3) Monoclonal, Unconjugated, Clone C3

RRID:AB_626665

Type: Antibody

Proper Citation

(Santa Cruz Biotechnology Cat# sc-8399, RRID:AB_626665)

Antibody Information

URL: http://antibodyregistry.org/AB_626665

Proper Citation: (Santa Cruz Biotechnology Cat# sc-8399, RRID:AB_626665)

Target Antigen: Human AFP

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: ELISA; Immunofluorescence; Immunoprecipitation; Western Blot; Western Blotting, Immunoprecipitation, Immunofluorescence, ELISA

Antibody Name: Mouse Anti-Human AFP (C3) Monoclonal, Unconjugated, Clone C3

Description: This monoclonal targets Human AFP

Target Organism: human

Clone ID: C3

Antibody ID: AB_626665

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-8399

Record Creation Time: 20231110T043818+0000

Record Last Update: 20241115T090242+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-Human AFP (C3) Monoclonal, Unconjugated, Clone C3.

No alerts have been found for Mouse Anti-Human AFP (C3) Monoclonal, Unconjugated, Clone C3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 37 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Pornratananont G, et al. (2024) Generation of integration-free human induced pluripotent stem cell line MURAI003-A derived from the peripheral blood mononuclear cells of a donor with homozygous Class I and Class II HLAs (A*11:01, B*46:01; C*01:02; DRB1*09:01; DQB1*03:03). Stem cell research, 80, 103514.

Sun W, et al. (2024) Generation of a TAB2 knockout hESC line (WAe009-A-Z) derived from H9 using CRISPR/Cas9. Stem cell research, 74, 103284.

Yanick C, et al. (2024) Generation of 3 patient induced Pluripotent stem cell lines containing SORD mutations linked to a recessive neuropathy. Stem cell research, 78, 103449.

Hua C, et al. (2024) Generation of a human induced pluripotent stem cell line ZZUNEU030-A from a female patient carrying a heterozygous CALM2 (c.395 A > T) mutation. Stem cell research, 81, 103515.

Lu F, et al. (2023) Generation of a FLNA knockout hESC line (WAe009-A-P) to model cardiac valvular dysplasia using CRISPR/Cas9. Stem cell research, 71, 103162.

Bai J, et al. (2023) Generation of a TRPM8 knockout hESC line (WAe009-A-A) derived from H9 using CRISPR/Cas9. Stem cell research, 67, 103040.

Begentas OC, et al. (2023) Generation and characterization of human induced pluripotent stem cell line METUi002-A from a patient with primary familial brain calcification (PFBC) carrying a heterozygous mutation (c.687dupT (p.Val230CysfsTer28)) in the SLC20A2 gene.

Stem cell research, 72, 103226.

Ruan Y, et al. (2023) Establishment of a human TLR4 compound heterozygous knockout hESC line (WAe009-A-N) to model toll-like receptor 4 deficiency by CRISPR/Cas9 system. Stem cell research, 73, 103225.

Zhu K, et al. (2023) An integration-free iPSC line ZZUNEUi029-A derived from peripheral blood mononuclear cells of a patient with familial hypercholesterolemia carrying a mutation in LDLR gene. Stem cell research, 71, 103182.

Dong Y, et al. (2022) Generation of an iPSC line (ZZUNEUi021-A) from a hypertrophic cardiomyopathy patient with TNNT2 mutation. Stem cell research, 58, 102622.

Liu Y, et al. (2022) Establishment of a human iPSC (ZZUNEUi026-A) from a dilated cardiomyopathy patient carrying heterozygous Vinculin (c. 625A > T) mutant. Stem cell research, 62, 102812.

Chumchuen S, et al. (2022) Establishment of human induced pluripotent stem cell line MUi028-A from normal fetal skin fibroblasts. Stem cell research, 60, 102675.

Cheng D, et al. (2022) An integration-free iPSC line ZZUNEUi028-A derived from a patient with hypertrophic cardiomyopathy carrying a heterozygous mutation (c. 1504 C > T) in MYBPC3 gene. Stem cell research, 63, 102848.

Hishida T, et al. (2022) In vivo partial cellular reprogramming enhances liver plasticity and regeneration. Cell reports, 39(4), 110730.

Begentas OC, et al. (2022) Establishment of Human Induced Pluripotent Stem Cells from Multiple Sclerosis Patients. Methods in molecular biology (Clifton, N.J.), 2549, 43.

Ding T, et al. (2022) Reprogramming of a human induced pluripotent stem cell line (ZZUSAHi004-A) from a long QT syndrome patient with a heterozygous AKAP9 (c. 4021C > A) mutant. Stem cell research, 65, 102966.

Zhao X, et al. (2022) A heterozygous MYBPC3 (c. 772+1G > A) mutant human induced pluripotent stem cell line (ZZUNEUi025-A) generated from a male patient with hypertrophic cardiomyopathy. Stem cell research, 60, 102722.

Zhao J, et al. (2022) Human induced pluripotent stem cell line ZZUNEUi027-A generated from a long QT syndrome patient with a heterozygous KCNH2 (c. 128 A > G) mutant. Stem cell research, 63, 102836.

Li X, et al. (2021) A heterozygous MYH7 (c. 2156G > A) mutant human induced pluripotent stem cell line (ZZUNEUi020-A) generated from a patient with hypertrophic cardiomyopathy. Stem cell research, 51, 102158.

Tian X, et al. (2021) Generation of a human iPSC line ZZUNEUi015-A from a patient with hypertrophic cardiomyopathy caused by mutation in ALPK3. Stem cell research, 52, 102247.